Insights

Investment Potential Ocugen has attracted significant investments from companies like Daiwa Securities Co. Ltd., indicating interest and confidence in Ocugen's gene and cell therapy platform. This presents a sales opportunity to leverage existing partnerships for further collaborations or investments.

Expanded Access Programs By launching expanded access programs for retinal disease treatments, Ocugen is demonstrating a commitment to improving patient outcomes. This initiative provides a sales opening to engage with healthcare providers and institutions to expand treatment accessibility.

Financial Growth With recent financing of $35 million through public offering, Ocugen showcases financial stability and growth potential. This financial health presents a sales opportunity for strategic partnerships, investments, or product development collaborations.

Market Expansion Ocugen's OCU410 program targeting geographic atrophy expands their gene therapy endeavors, tapping into new market segments. This diversification offers a sales opportunity to explore partnerships, licensing agreements, or market entry strategies in the ophthalmology sector.

Competitive Positioning By addressing legal challenges and ensuring transparency, Ocugen can strengthen its competitive position in the biotechnology landscape. This positive image enhancement can aid sales efforts by building trust with potential partners and investors.

Similar companies to Ocugen

Ocugen Tech Stack

Ocugen uses 8 technology products and services including jQuery CDN, Microsoft Outlook, jQuery, and more. Explore Ocugen's tech stack below.

jQuery CDN
Content Delivery Network
Microsoft Outlook
Email
jQuery
Javascript Libraries
Underscore.js
Javascript Libraries
Leaflet
Maps
Hootsuite
Marketing
PHP
Programming Languages
Facebook
Widgets

Media & News

Ocugen's Email Address Formats

Ocugen uses at least 1 format(s):

Ocugen Email Formats	Example	Percentage
First.Last@ocugen.com	John.Doe@ocugen.com	91%
FirstLast@ocugen.com	JohnDoe@ocugen.com	4%
First@ocugen.com	John@ocugen.com	4%
Fir.Last@ocugen.com	Joh.Doe@ocugen.com	1%

Frequently Asked Questions

Where is Ocugen's headquarters located?

Ocugen's main headquarters is located at 263 Great Valley Pkwy Malvern, Pennsylvania 19355 US. The company has employees across 4 continents, including North AmericaAsiaEurope.

What is Ocugen's phone number?

You can contact Ocugen's main corporate office by phone at

+1-484-328-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Ocugen's stock symbol?

Ocugen is a publicly traded company; the company's stock symbol is OCGN.

What is Ocugen's official website and social media links?

Ocugen's official website is ocugen.com and has social profiles on LinkedIn.

How much revenue does Ocugen generate?

As of September 2024, Ocugen's annual revenue reached $35M.

What is Ocugen's SIC code NAICS code?

Ocugen's SIC code is 3423 - Hand and Edge Tools, Except Machine Tools and Handsaws NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Ocugen have currently?

As of September 2024, Ocugen has approximately 79 employees across 4 continents, including North AmericaAsiaEurope. Key team members include Chief Scientific Officer: A. U.President: C. B.Co-Founder: U. K.. Explore Ocugen's employee directory with LeadIQ.

What industry does Ocugen belong to?

Ocugen operates in the Biotechnology Research industry.

What technology does Ocugen use?

Ocugen's tech stack includes jQuery CDNMicrosoft OutlookjQueryUnderscore.jsLeafletHootsuitePHPFacebook.

What is Ocugen's email format?

Ocugen's email format typically follows the pattern of . Find more Ocugen email formats with LeadIQ.

How much funding has Ocugen raised to date?

As of September 2024, Ocugen has raised $35M in funding. The last funding round occurred on Jul 31, 2024 for $35M.

When was Ocugen founded?

Ocugen was founded in 2013.

Ocugen

Biotechnology ResearchPennsylvania, United States51-200 Employees

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs.

Company Overview

Headquarters: 263 Great Valley Pkwy Malvern, Pennsylvania 19355 US
Phone number: ✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
+1-484-328-****
Website: ocugen.com
SIC Code: 3423 - Hand and Edge Tools, Except Machine Tools and Handsaws
Stock Symbol: OCGN
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2013
Employees: 51-200

Media & News

Funding & Financials

$35M
Ocugen has raised a total of $35M of funding over 7 rounds. Their latest funding round was raised on Jul 31, 2024 in the amount of $35M.
$10M$50M
Ocugen's revenue is in the range of $10M$50M

Funding & Financials

$35M
Ocugen has raised a total of $35M of funding over 7 rounds. Their latest funding round was raised on Jul 31, 2024 in the amount of $35M.
$10M$50M
Ocugen's revenue is in the range of $10M$50M

Company Leadership

A. U.
Chief Scientific Officer
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
C. B.
President
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
U. K.
Co-Founder
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
P. S.
Senior Director, Head Of Product Development
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
T. H.
Avp, Head Of Corporate Communications
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Employee Directory

M. S.
Senior Vice President, Commercial
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
D. D.
Vp, Manufacturing
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
J. P.
Vp Quality Assurance & Regulatory Affairs
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
M. S.
Senior Vice President Commercial
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
P. C. N.
Director (pre-Clinical Development; Nanobiotechnology; Program Lead)
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Ocugen and Millions of Other Companies
Sign up for full access to Ocugen information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Go to Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Ocugen

OncoSec

Fortress Biotech

Sanofi Pasteur

Agenus

Ocugen Tech Stack

Media & News

Daiwa Securities Co. Ltd. invests into Ocugen, Inc..

Ocugen, Inc. launches expanded access program for retinitis treatment.

Ocugen, Inc. receives financing of $35M in public offering.

Glancy Prongay & Murray LLP files suit against Ocugen, Inc..

Ocugen, Inc. launches OCU410 program targeting geographic atrophy.

Robbins LLP files suit against Ocugen, Inc..

Ocugen, Inc. has issues with securities fraud or other unlawful business practices.

Ocugen's Email Address Formats

Frequently Asked Questions

Where is Ocugen's headquarters located?

What is Ocugen's phone number?

What is Ocugen's stock symbol?

What is Ocugen's official website and social media links?

How much revenue does Ocugen generate?

What is Ocugen's SIC code NAICS code?

How many employees does Ocugen have currently?

What industry does Ocugen belong to?

What technology does Ocugen use?

What is Ocugen's email format?

How much funding has Ocugen raised to date?

When was Ocugen founded?

Ocugen

Company Overview

Media & News

Daiwa Securities Co. Ltd. invests into Ocugen, Inc..

Ocugen, Inc. launches expanded access program for retinitis treatment.

Ocugen, Inc. receives financing of $35M in public offering.

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?